Profile data is unavailable for this security.
About the company
Serina Therapeutics, Inc., formerly AgeX Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Its POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. Its POZ Platform partners are at the forefront in advancing LNP delivery technology to develop RNA therapeutics. The Company is focused on the advancement of its lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinson’s Disease through pre-clinical studies. The Company intends to advance SER 252 into Phase I clinical trials.
- Revenue in USD (TTM)179.00k
- Net income in USD-18.67m
- Incorporated2017
- Employees4.00
- LocationSerina Therapeutics Inc1101 MARINA VILLAGE PARKWAY, SUITE 201ALAMEDA 94501United StatesUSA
- Phone+1 (510) 671-8370
- Websitehttps://www.agexinc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reneo Pharmaceuticals Inc | 0.00 | -56.54m | 50.48m | 8.00 | -- | 0.6565 | -- | -- | -1.68 | -1.68 | 0.00 | 2.30 | 0.00 | -- | -- | 0.00 | -49.87 | -- | -53.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Allakos Inc | 0.00 | -206.00m | 51.20m | 131.00 | -- | 0.6096 | -- | -- | -2.35 | -2.35 | 0.00 | 0.9454 | 0.00 | -- | -- | 0.00 | -86.62 | -42.71 | -99.21 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Serina Therapeutics Inc | 179.00k | -18.67m | 52.93m | 4.00 | -- | -- | -- | 295.72 | -9.72 | -9.72 | 0.0403 | -1.86 | 0.0156 | -- | 6.28 | 44,750.00 | -162.58 | -194.46 | -- | -- | 49.72 | 85.80 | -10,438.55 | -2,347.36 | -- | -1.82 | -- | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 4.15m | -131.56m | 53.08m | 68.00 | -- | -- | -- | 12.80 | -4.30 | -4.30 | 0.1222 | -0.2369 | 0.0288 | -- | -- | 61,000.00 | -91.46 | -54.44 | -112.06 | -64.32 | -- | -- | -3,171.70 | -772.82 | -- | -- | 1.18 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Prenetics Global Ltd | 22.25m | -49.97m | 53.27m | 320.00 | -- | 0.2325 | -- | 2.39 | -4.33 | -5.32 | 1.91 | 18.75 | 0.0832 | 3.89 | 4.53 | 69,535.41 | -19.43 | -- | -23.55 | -- | 45.56 | -- | -233.41 | -- | 2.25 | -5.17 | 0.0086 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -9.35m | 53.94m | 2.00 | -- | 10.82 | -- | -- | -0.3633 | -0.3633 | 0.00 | 0.1922 | 0.00 | -- | -- | 0.00 | -91.51 | -- | -104.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
| Angion Biomedica Corp | 0.00 | -38.66m | 55.38m | 32.00 | -- | -- | -- | -- | -4.83 | -4.83 | 0.00 | -0.161 | 0.00 | -- | -- | 0.00 | -144.89 | -105.91 | -202.49 | -331.69 | -- | -- | -- | -712.81 | -- | -- | -- | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -15.08m | 56.19m | 5.00 | -- | 10.47 | -- | -- | -1.10 | -1.10 | 0.00 | 0.3898 | 0.00 | -- | -- | 0.00 | -112.08 | -- | -146.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Hookipa Pharma Inc | 52.16m | -48.60m | 56.90m | 151.00 | -- | 0.6611 | -- | 1.09 | -5.28 | -5.28 | 4.85 | 7.14 | 0.33 | -- | 309.57 | 345,450.30 | -30.74 | -41.63 | -40.15 | -50.26 | -- | -- | -93.16 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Kronos Bio Inc | 8.41m | -102.85m | 57.14m | 58.00 | -- | 0.4638 | -- | 6.79 | -1.75 | -1.75 | 0.1425 | 2.04 | 0.0396 | -- | -- | 135,661.30 | -48.41 | -35.47 | -53.26 | -37.14 | -- | -- | -1,222.83 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Aerovate Therapeutics Inc | 0.00 | -87.94m | 57.16m | 51.00 | -- | 0.6052 | -- | -- | -3.14 | -3.14 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -65.76 | -- | -74.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| VolitionRX Ltd | 976.52k | -32.42m | 58.48m | 110.00 | -- | -- | -- | 59.89 | -0.4032 | -0.4032 | 0.0121 | -0.263 | 0.0481 | -- | 5.38 | 8,877.45 | -161.39 | -111.92 | -- | -196.20 | -- | -- | -3,357.34 | -10,793.31 | -- | -129.66 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
Data as of Sep 20 2024. Currency figures normalised to Serina Therapeutics Inc's reporting currency: US Dollar USD
2.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Broadwood Capital, Inc.as of 30 Jun 2024 | 85.22k | 0.96% |
| Waverly Advisors LLC (Alabama)as of 30 Jun 2024 | 23.49k | 0.26% |
| Geode Capital Management LLCas of 30 Jun 2024 | 22.75k | 0.26% |
| Hightower Advisors LLCas of 30 Jun 2024 | 22.48k | 0.25% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 21.76k | 0.25% |
| Millennium Management LLCas of 30 Jun 2024 | 21.67k | 0.24% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.98k | 0.05% |
| Tower Research Capital LLCas of 30 Jun 2024 | 1.96k | 0.02% |
| British & American Investment Trust Plc (Invt Mgmt)as of 31 Dec 2023 | 1.10k | 0.01% |
| UBS Securities LLCas of 30 Jun 2024 | 1.02k | 0.01% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
